Most Common Adverse Events6

The most frequently reported adverse reactions (≥25%) in clinical trials were dizziness, nausea, confusional state, and nystagmus. Slower titration of PRIALT may result in fewer serious adverse reactions and discontinuation of PRIALT for adverse reactions. Adverse reactions during the slow titration placebo-controlled trial are summarized in the table below.

Incidence of adverse reactions in the slow titration placebo-controlled trial by percent (events that occurred in ≥5% of patients and more commonly with PRIALT than with placebo)

Please see full Prescribing Information, including BOXED Warning, and click here for additional Important Safety Information.

Reference: 6. PRIALT [package insert]. Palo Alto, CA: Jazz Pharmaceuticals; February 2013.
Patient Demographics
Efficacy Results
Discontinuation Rates
Adverse Events